Treatment outcomes of stereotactic body radiation therapy for primary and metastatic sarcoma of the spine

Radiation Oncology

Table 5 Results of spine SBRT for sarcoma patients

Study	Time period	Number of patients	Number of lesions	Predominant histology of lesions	Dose fractionation	Median follow-up	Local control	Overall survival
Folkert et al. 10	2005–2012	88	120	Leiomyosarcoma (30%), Other/spindle-cell (18%), Hemangiopericytoma/solitary fibrous tumor (16%)	18–24 Gy/1 fx 24–36 Gy/3–6 fx	12.3 months	1-year 87.9%	1-year 60.6%
Miller et al. 11	2005–2012	18	36	Leiomyosarcoma (32%), Chondrosarcoma (17%), Spindle cell (17%)	Median 16 Gy/1 fx (range, 10–25 Gy/1–5 fx)	15 months	1-year 50%	1-year 60%
Bishop et al. 12	2002–2013	48	66	Leiomyosarcoma (42%), Epithelioid (14%), MFH/UPS (12%)	BED: < 50 Gy₁₀ (n = 11), 50–59 Gy₁₀ (n = 40), ≥ 60 Gy₁₀ (n = 15)	19 months	1-year 81%	1-year 67%
Elibe et al. 13	2001–2013	23	53	Leiomyosarcoma (39%), Ewing’s (13%)	Median 18 Gy/1 fx (range, 10–20 Gy/1 fx)	14 months	Overall 67%	Median 15.5 months
This study	2006–2017	44	75	Osteosarcoma (57%), MPNST (12%)	Median 33 Gy/3 fx (range, 18–45 Gy/1–5 fx)	18.2 months	1-year 76.4%	1-year 80.5%

MFH malignant fibrous histiocytomas, UPS undifferentiated pleomorphic sarcoma, MPNST malignant peripheral nerve sheath tumor

ISSN: 1748-717X